CR20240226A - Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa - Google Patents

Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa

Info

Publication number
CR20240226A
CR20240226A CR20240226A CR20240226A CR20240226A CR 20240226 A CR20240226 A CR 20240226A CR 20240226 A CR20240226 A CR 20240226A CR 20240226 A CR20240226 A CR 20240226A CR 20240226 A CR20240226 A CR 20240226A
Authority
CR
Costa Rica
Prior art keywords
macrocyclic compounds
inhibitory activity
same
farnesyltransferase inhibitory
farnesyltransferase
Prior art date
Application number
CR20240226A
Other languages
English (en)
Inventor
Zhu Bai
Dan Xu
Yahu Arthur Liu
Wanting Xiong
Xuefeng Zhu
Pingda Ren
Original Assignee
Kura Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kura Oncology Inc filed Critical Kura Oncology Inc
Publication of CR20240226A publication Critical patent/CR20240226A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos macrocíclicos de una cualquiera de la fórmula (I), o una forma farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden los mismos, métodos para preparar los mismos, y métodos para tratar el cáncer dependiente de una proteína farnesilada, utilizando los mismos.
CR20240226A 2021-11-30 2022-11-29 Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa CR20240226A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202111442658 2021-11-30
US202163285412P 2021-12-02 2021-12-02
CN202211471486 2022-11-23
US202263385117P 2022-11-28 2022-11-28
PCT/US2022/080565 WO2023102378A1 (en) 2021-11-30 2022-11-29 Macrocyclic compounds having farnesyltransferase inhibitory activity

Publications (1)

Publication Number Publication Date
CR20240226A true CR20240226A (es) 2024-07-01

Family

ID=84981542

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240226A CR20240226A (es) 2021-11-30 2022-11-29 Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa

Country Status (15)

Country Link
US (2) US12018011B2 (es)
EP (1) EP4441038A1 (es)
JP (1) JP2024544059A (es)
KR (1) KR20240110978A (es)
CN (1) CN119504706A (es)
AU (1) AU2022399572A1 (es)
CA (1) CA3234276A1 (es)
CL (1) CL2024001565A1 (es)
CO (1) CO2024006727A2 (es)
CR (1) CR20240226A (es)
DO (1) DOP2024000102A (es)
IL (1) IL312132A (es)
MX (1) MX2024005822A (es)
TW (1) TW202327590A (es)
WO (1) WO2023102378A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3157525A1 (en) 2019-10-25 2021-04-29 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
PH12023552860A1 (en) 2021-04-21 2024-05-20 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
EP4698173A1 (en) * 2023-04-20 2026-02-25 Kura Oncology, Inc. Treatment of non-small cell lung cancer with a combination of 3-amino-3-(1-methyl-1h-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-22,44-dicarbonitrile and an egfr-tki
WO2024233539A1 (en) * 2023-05-09 2024-11-14 Kura Oncology, Inc. Methods of treating squamous cell carcinoma with a farnesyltransferase inhibitor and a pi3k inhibitor
AU2024220205A1 (en) * 2023-05-31 2024-12-19 Kura Oncology, Inc. Solid forms of a macrocyclic farnesyltransferase inhibitor and formulations thereof, and methods of preparing and using the macrocyclic compound and its solid forms
EP4719410A1 (en) 2023-05-31 2026-04-08 Kura Oncology, Inc. Farnesyltransferase inhibitors for treatment of kras-dependent cancers

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CA2316273A1 (en) 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Sustained-release composition, method of its production and use thereof
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN102112445B (zh) 2008-06-09 2014-06-18 百时美施贵宝公司 作为抗细胞凋亡Bcl抑制剂的羟基苯基磺酰胺

Also Published As

Publication number Publication date
US20240287023A1 (en) 2024-08-29
KR20240110978A (ko) 2024-07-16
US12018011B2 (en) 2024-06-25
US20230322711A1 (en) 2023-10-12
AU2022399572A1 (en) 2024-05-02
DOP2024000102A (es) 2024-06-30
CL2024001565A1 (es) 2024-09-06
WO2023102378A1 (en) 2023-06-08
JP2024544059A (ja) 2024-11-27
MX2024005822A (es) 2024-05-28
IL312132A (en) 2024-06-01
EP4441038A1 (en) 2024-10-09
CN119504706A (zh) 2025-02-25
CA3234276A1 (en) 2023-06-08
CO2024006727A2 (es) 2024-07-18
TW202327590A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
DOP2024000102A (es) Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
BR112019000247A2 (pt) derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores
DOP2020000112A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
MX2024008886A (es) Sulfonamida sustituida con trifluorometilo como inhibidor selectivo de bcl-2.
BR112021017620A2 (pt) Compostos macrocíclicos
AR127470A1 (es) Inhibidores de lrrk2
UY37569A (es) Inhibidores del inmunoproteasoma
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
MX2024007929A (es) Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.
BR112018076257A2 (pt) compostos e composições farmacêuticas
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
CL2025002792A1 (es) Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.
AR130274A1 (es) Degradadores cdk2 y usos de los mismos